GERN Stock — Geron Corporation

Geron Corporation (GERN)

Updated October 16, 2026.

GERN is a Stock. Total return is -84.0% over the past 30.2 years, 1986.0 points behind SPY at 1902.0%.

Geron Corporation is a commercial-stage biopharmaceutical company developing cancer therapeutics, with an approved product (RYTELO, a telomerase inhibitor for myelodysplastic syndromes) and a pipeline of candidates in Phase 1 through Phase 3 clinical trials targeting blood cancers and bone marrow disorders. The company does not currently distribute dividends to shareholders. Geron's stock is appropriate for investors seeking exposure to clinical-stage biotech development rather than current income.

GERN performance versus SPY

Price and return data through 2026-10-16.

Total return is -84.0% over the past 30.2 years, 1986.0 points behind SPY at 1902.0%. Over the past year its total return — price change plus distributions reinvested — is -4.9%. Its deepest 1-year drawdown was 43.6%.

GERN key facts

Asset type

Stock

Asset class

Equity

Inception date

07/31/1996

Distribution frequency

None

Last close

$1.17 (as of 2026-10-16)

Market cap

$751,693,889

Average volume

3948156.0

Beta

0.611

Payout ratio

0.0%

Forward P/E

65.3595

EPS

$-0.11

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GERN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 43.6%.

Who may consider GERN — and who may not

It is a weaker fit for investors who need monthly cash flow (GERN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GERN

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions